How Does Glutathione Work? Mechanism of Action, Per the Research

The short answer from the literature

Glutathione (GSH) is a tripeptide built from glutamate, cysteine and glycine, and almost all of its described biology traces back to the single thiol (–SH) group on its cysteine residue. Published pharmacology does not describe glutathione as a ligand for a classical G-protein-coupled or tyrosine-kinase receptor. Instead, it is described as a substrate, cofactor and nucleophile used by whole enzyme families. A 2013 review of the glutathione peroxidase family reported that these selenocysteine- and cysteine-containing enzymes reduce hydroperoxides using glutathione as the reducing substrate, positioning GSH as the electron donor in peroxide detoxification (PMID 23201771). A separate 2021 review described glutathione S-transferases as the enzymes that conjugate GSH to electrophilic compounds, a core phase II detoxification route that also intersects with cancer cell signalling (PMID 33946704).

This page summarises what the published literature describes as mechanism. It separates well-established enzymology from proposed or context-specific signalling, and it labels in-vitro and animal work as such. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions.

Established mechanism 1: glutathione as the reducing substrate for peroxidases

The most consistently described function of glutathione in the literature is as an electron donor. The 2013 glutathione peroxidase review reported that the GPX family catalyses the reduction of hydrogen peroxide and organic hydroperoxides, with glutathione oxidised to its disulphide dimer (GSSG) in the process, and that different family members differ in substrate preference and subcellular location (PMID 23201771). The same review described GPX enzymes as participants in redox signalling rather than as simple scavengers, because the peroxides they remove are themselves second messengers (PMID 23201771).

Two consequences follow from this chemistry, both described in the cited literature. First, the ratio of reduced GSH to oxidised GSSG — not GSH concentration alone — is the quantity researchers use to describe cellular redox state; a 2020 review on the quantitative redox biology of exercise argued that redox species including glutathione should be measured quantitatively rather than inferred from indirect markers (PMID 32455453). Second, glutathione must be regenerated for the system to keep working. The regeneration chemistry is conserved far beyond mammals: a 2024 review in plant biology described the ascorbate–glutathione cycle, in which GSSG is reduced back to GSH by glutathione reductase using NADPH while ascorbate is recycled in parallel (PMID 38243395). That review is plant work and is cited here only as an illustration of the recycling logic, not as human physiology (PMID 38243395).

Established mechanism 2: GPX4, lipid hydroperoxides and ferroptosis

One peroxidase in particular has dominated recent mechanistic literature. A 2020 review of ferroptosis in cancer cell biology described GPX4 as the enzyme that uses glutathione to reduce phospholipid hydroperoxides within membranes, and reported that loss of GPX4 activity or depletion of its glutathione supply permits iron-dependent lipid peroxidation and the regulated cell death called ferroptosis (PMID 31936571). The same review described cystine import through system x_c⁻ as the upstream step that supplies cysteine for glutathione synthesis, linking amino acid transport to ferroptosis sensitivity (PMID 31936571).

Regulation of the GSH–GPX4 axis in preclinical models

Several cell-based and animal studies have mapped the control points around this axis. A 2023 study in Nature Cell Biology reported that creatine kinase B suppressed ferroptosis by phosphorylating GPX4 through a moonlighting kinase function, describing a post-translational control point on the enzyme itself in cancer cell models (PMID 37156912). A 2022 study reported that thiostrepton induced ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling, an in-vitro and preclinical finding rather than a human one (PMID 35859150).

Context also matters. A 2019 Nature paper reported that intercellular interaction dictated cancer cell ferroptosis via NF2–YAP signalling, meaning that cell density and adhesion state changed how sensitive cells were to lipid peroxidation independent of any change in glutathione supply (PMID 31341276). A 2025 study reported that salidroside sensitised triple-negative breast cancer models to ferroptosis through SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy, implicating lipid composition and iron handling as parallel determinants alongside the glutathione–GPX4 arm (PMID 39353532). Readers should note that all four of those reports are cancer-cell or animal studies and were not designed to describe what a glutathione product does in a healthy person (PMID 31341276, PMID 39353532).

Established mechanism 3: conjugation by glutathione S-transferases

The second major enzymatic use of glutathione is chemical conjugation. The 2021 review of glutathione S-transferases in cancer reported that GST isoenzymes catalyse the attachment of GSH to electrophilic substrates, producing more water-soluble conjugates for export and elimination, and that GST expression patterns have been studied in the context of tumour biology and drug resistance (PMID 33946704). That review also described non-catalytic roles for GST proteins in signalling complexes, which is why researchers treat GSTs as more than passive detoxification enzymes (PMID 33946704).

Mechanistically, this is the same thiol chemistry seen in peroxide reduction, used differently: the cysteine sulphur attacks an electrophilic centre instead of a peroxide bond. It is the reason glutathione appears in both antioxidant and xenobiotic-handling chapters of pharmacology texts, and why GST activity is one of the variables researchers consider when interpreting glutathione pool measurements (PMID 33946704).

Downstream signalling described in the literature

Cell-death signalling

A 2008 review titled "Glutathione and apoptosis" reported that changes in the glutathione pool — including depletion and transport of GSH out of the cell — accompany apoptotic signalling, and described the mitochondrial glutathione pool as functionally distinct from the cytosolic pool (PMID 18671159). The review framed glutathione loss as part of the regulatory sequence of apoptosis rather than as a simple by-product of oxidative damage (PMID 18671159).

Nrf2/HO-1 and transcriptional control

Because glutathione synthesis enzymes are under Nrf2 control, much of the upstream signalling literature is written in terms of that pathway. A 2024 study reported that vitamin D receptor activation attenuated renal tubular epithelial cell ferroptosis by regulating Nrf2/HO-1 signalling in models of diabetic nephropathy (PMID 38145959). That work was conducted in cell and animal models of kidney disease, and the study described a transcriptional route by which antioxidant capacity — including the machinery that supports glutathione-dependent peroxidases — can be raised or lowered (PMID 38145959).

Inflammatory stress signalling

Redox-sensitive stress pathways intersect with innate immune signalling. A 2024 paper in Cell reported that STING orchestrated the neuronal inflammatory stress response in multiple sclerosis, describing a stress-response programme in neurons under inflammatory conditions (PMID 38878778). That study is cited here as an example of the stress-signalling context in which glutathione-dependent enzymes operate; it was not a glutathione supplementation trial (PMID 38878778).

Established versus proposed: a summary table

What the cited mechanism literature does not establish

The papers summarised here are enzymology reviews and preclinical mechanistic studies. They describe what glutathione does inside cells; they do not describe the pharmacokinetics of any glutathione product, nor do they report clinical outcomes. The ferroptosis studies cited above were conducted in cancer cells or disease models and were designed to identify death-pathway control points, not to characterise supplementation (PMID 35859150, PMID 39353532). The exercise redox review highlighted that redox measurements are frequently over-interpreted and called for quantitative methodology, which is a direct caution against reading broad physiological conclusions from single glutathione markers (PMID 32455453).

A second nuance is directionality. Because glutathione supports GPX4, more glutathione availability is associated in these models with resistance to ferroptosis, which is desirable in some tissues and the opposite of the therapeutic aim in oncology models where researchers deliberately sensitised tumour cells to ferroptosis (PMID 31936571, PMID 39353532). Mechanism, in other words, is context-dependent rather than uniformly "good".

Mechanistic Studies and Safety Signals: What Studies Report

The verified papers cited on this page are mechanistic reviews and preclinical investigations; they reported enzyme kinetics, signalling pathways and cell-death endpoints rather than human adverse-event tables (PMID 23201771, PMID 31936571). Where cytotoxicity appeared in these studies it was the intended experimental outcome in tumour models — for example, the 2022 report of thiostrepton-induced ferroptosis in pancreatic cancer cells (PMID 35859150) and the 2025 report of salidroside-sensitised triple-negative breast cancer models (PMID 39353532). Reviews of glutathione S-transferases also discussed the pathway's involvement in chemotherapy resistance, another reason researchers treat glutathione status as context-specific (PMID 33946704). No dosing information is presented on this page because the cited papers do not supply human dosing data.

How to read mechanism claims about glutathione

1. Ask which enzyme is doing the work. Most glutathione effects described in the literature are attributed to a peroxidase or transferase, not to GSH acting alone (PMID 23201771).
2. Ask whether the model was human. The GPX4 regulation findings came from cancer cell systems (PMID 37156912).
3. Ask whether the ratio was measured. The exercise redox review emphasised quantitative measurement over surrogate markers (PMID 32455453).
4. Ask which direction is desirable in that tissue. Ferroptosis resistance and ferroptosis sensitivity are opposite goals across the cited studies (PMID 31341276).

References

• Glutathione peroxidases (Biochimica et Biophysica Acta, 2013)
• Ferroptosis in Cancer Cell Biology (Cancers, 2020)
• Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function (Nature Cell Biology, 2023)
• Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling (Cell Death & Disease, 2022)
• Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling (Nature, 2019)
• Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy (Journal of Advanced Research, 2025)
• Glutathione S-Transferases in Cancer (Antioxidants, 2021)
• Glutathione and apoptosis (Free Radical Research, 2008)
• VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf2/HO-1 Signaling Pathway in Diabetic Nephropathy (Advanced Science, 2024)
• STING orchestrates the neuronal inflammatory stress response in multiple sclerosis (Cell, 2024)
• The ascorbate-glutathione cycle coming of age (Journal of Experimental Botany, 2024)
• Quantitative Redox Biology of Exercise (International Journal of Sports Medicine, 2020)